CytoDyn’s Promotion Of Investigational Drug Leronlimab Once Again Rebuked By US FDA

 
• By Brenda Sandburg

OPDP warning letter objects to video interview in which CytoDyn's then CEO touts use of the investigational drug for COVID-19. The exec says he is ‘making up numbers’ but if the pattern continues there will be ‘the most fantastic results’ anybody could ever imagine.

Monoclonal antibody
CytoDyn video promotion for its investigational COVID-19 treatment draws FDA warning letter • Source: Alamy

More from Archive

More from Pink Sheet